# US 2021/0171630 A1 · Bispecific CD16-Binding Molecules and Their Use in the Treatment of Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171630 A1
- Document ID: US20210171630A1
- Status: Published application
- Kind: A1
- Application number: 16/771,377
- Filed: 2018-12-06
- Published: 2021-06-10
- Earliest claimed: 2017-12-12
- Assignees: MacroGenics, Inc.
- Applicants: MacroGenics, Inc.
- Inventors: Gundo Diedrich; Liqin Liu; Hua Watson Li; Leslie S. Johnson
- Web page: https://patentgrep.com/patent/US20210171630A1

## CPC

- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- C07K 16/11: Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
- C07K 16/114: Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/32: against translation products of oncogenes
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/626: Diabody or triabody
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/73: containing coiled-coiled motif (leucine zippers)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to molecules (e.g., an antibody, a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding an epitope of human CD16 (a “CD16 Binding Molecule”). The present invention is further directed to CD 16 Binding Molecules that are capable of binding an epitope of human CD16 and one or more epitope(s) of a Disease Antigen (“DA”) (e.g., a “CD16 x DA Binding Molecule”). The present invention is particularly directed to such CD16 x DA Binding Molecules that are antibodies, or that comprise an Epitope Binding Domain thereof, or are diabodies (including DART® diabodies), bispecific antibodies, TandAbs, other multispecific binding molecules (e.g., trivalent TRIDENT™ molecules), etc. The invention particularly concerns CD16 x DA Binding Molecules that are capable of binding a Disease Antigen that is a Cancer Antigen or a Pathogen-Associated Antigen in addition to being able to bind CD 16. The invention particularly concerns the use of such CD16 and CD16 x DA Binding Molecules in the treatment of cancer and pathogen-associated diseases. The present invention is also directed to pharmaceutical compositions that comprise such molecule(s).

## Claims

### Claim 1

A CD16 x Disease Antigen (CD16 x DA) Binding Molecule comprising a CD16 Binding Domain capable of binding an epitope of CD16 and also a Disease Antigen-Binding Domain capable of binding an epitope of a Disease Antigen, wherein said CD16 Binding Domain comprises one or more of:
(I) (A) a CDRH1 Domain comprising the amino acid sequence of SEQ ID NO:66;
(B) a CDRH2 Domain comprising the amino acid sequence of SEQ ID NO:67;
(C) a CDRH3 Domain comprising the amino acid sequence of SEQ ID NO:68 or SEQ ID NO:60;
(D) a CDRL1 Domain comprising the amino acid sequence of SEQ ID NO:69 or SEQ ID NO:74;
(E) a CDRL2 Domain comprising the amino acid sequence of SEQ ID NO:70; and
(F) a CDRL3 Domain comprising the amino acid sequence of SEQ ID NO:71 or SEQ ID NO:61;
(II) (A) a CDRH1 Domain comprising the amino acid sequence of SEQ ID NO:77;
(B) a CDRH2 Domain comprising the amino acid sequence of SEQ ID NO:78;
(C) a CDRH3 Domain comprising the amino acid sequence of SEQ ID NO:79;
(D) a CDRL1 Domain comprising the amino acid sequence of SEQ ID NO:80;
(E) a CDRL2 Domain comprising the amino acid sequence of SEQ ID NO:81; and
(F) a CDRL3 Domain comprising the amino acid sequence of SEQ ID NO:82;
(III) a VH Domain comprising the amino acid sequence of SEQ ID NO:72, SEQ ID NO:83, SEQ ID NO:84, or SEQ ID NO:58;
(IV) a VL Domain comprising the amino acid sequence of SEQ ID NO:73, SEQ ID NO:85, or SEQ ID NO:59;
(V) a VH Domain comprising the amino acid sequence of SEQ ID NO:72 and a VL Domain comprising the amino acid sequence of SEQ ID NO:73;
(VI) a VH Domain comprising the amino acid sequence of SEQ ID NO:83 or SEQ ID NO:84 and a VL Domain comprising the amino acid sequence of SEQ ID NO:85;
(VII) a VH Domain comprising the amino acid sequence of SEQ ID NO:58 and a VL Domain comprising the amino acid sequence of SEQ ID NO:73;
(VIII) a VH Domain comprising the amino acid sequence of SEQ ID NO:72 and a VL Domain comprising the amino acid sequence of SEQ ID NO:59; and
(IX) a VH Domain comprising the amino acid sequence of SEQ ID NO:58 and a VL Domain comprising the amino acid sequence of SEQ ID NO:59.

### Claim 2 (depends on 1)

The CD16 x Disease Antigen Binding Molecule of claim 1, wherein said Molecule is a bispecific antibody, a bispecific diabody, a bispecific TandAb, a bispecific trivalent molecule, or a bispecific CAR.

### Claim 3 (depends on 1, 2)

The CD16 x Disease Antigen Binding Molecule of any one of claims 1-2, wherein said Molecule is capable of binding more than one Disease Antigen and/or more than one epitope of CD16.

### Claim 4 (depends on 1, 2, 3)

The CD16 x Disease Antigen Binding Molecule of any one of claims 1-3, wherein said CD16 Binding Domain comprises:
(A) a CDRH1 Domain comprising the amino acid sequence of SEQ ID NO:66;
(B) a CDRH2 Domain comprising the amino acid sequence of SEQ ID NO:67;
(C) a CDRH3 Domain comprising the amino acid sequence of SEQ ID NO:68, or SEQ ID NO:60;
(D) a CDRL1 Domain comprising the amino acid sequence of SEQ ID NO:69 or SEQ ID NO:74;
(E) a CDRL2 Domain comprising the amino acid sequence of SEQ ID NO:70; and
(F) a CDRL3 Domain comprising the amino acid sequence of SEQ ID NO:71, or SEQ ID NO:61.

### Claim 5 (depends on 1, 2, 3)

The CD16 x Disease Antigen Binding Molecule of any one of claims 1-3, wherein said CD16 Binding Domain comprises:
(A) a VH Domain comprising the amino acid sequence of SEQ ID NO:72, or SEQ ID NO:58;
(B) a VL Domain comprising the amino acid sequence of SEQ ID NO:73, or SEQ ID NO:59;
(C) a VH Domain comprising the amino acid sequence of SEQ ID NO:72 and a VL Domain comprising the amino acid sequence of SEQ ID NO:73;
(D) a VH Domain comprising the amino acid sequence of SEQ ID NO:58 and a VL Domain comprising the amino acid sequence of SEQ ID NO:73;
(E) a VH Domain comprising the amino acid sequence of SEQ ID NO:72 and a VL Domain comprising the amino acid sequence of SEQ ID NO:59; or
(F) a VH Domain comprising the amino acid sequence of SEQ ID NO:58 and a VL Domain comprising the amino acid sequence of SEQ ID NO:59.

### Claim 6 (depends on 1, 2, 3)

The CD16 x Disease Antigen Binding Molecule of any one of claims 1-3, wherein said CD16 Binding Domain comprises:
(A) a CDRH1 Domain comprising the amino acid sequence of SEQ ID NO:77;
(B) a CDRH2 Domain comprising the amino acid sequence of SEQ ID NO:78;
(C) a CDRH3 Domain comprising the amino acid sequence of SEQ ID NO:79;
(D) a CDRL1 Domain comprising the amino acid sequence of SEQ ID NO:80;
(E) a CDRL2 Domain comprising the amino acid sequence of SEQ ID NO:81; and
(F) a CDRL3 Domain comprising the amino acid sequence of SEQ ID NO:82.

### Claim 7 (depends on 1, 2, 3)

The CD16 x Disease Antigen Binding Molecule of any one of claims 1-3, wherein said CD16 Binding Domain comprises:
(A) a VH Domain comprising the amino acid sequence of SEQ ID NO:83, or SEQ ID NO:84;
(B) a VL Domain comprising the amino acid sequence of or SEQ ID NO:85; or
(C) a VH Domain comprising the amino acid sequence of SEQ ID NO:83 or SEQ ID NO:84 and a VL Domain comprising the amino acid sequence of SEQ ID NO:85.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The CD16 x Disease Antigen Binding Molecule of any one of claims 1-7, wherein said Disease Antigen is a Cancer Antigen and said disease is cancer.

### Claim 9 (depends on 6)

The CD16 x Disease Antigen Binding Molecule of claim 6, wherein said cancer is selected from the group consisting of adrenal cancer, bladder cancer, breast cancer, colorectal cancer, gastric cancer, glioblastoma, kidney cancer, non-small-cell lung cancer, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, Burkett's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, non-Hodgkin's lymphoma, small lymphocytic lymphoma, multiple myeloma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, renal cell carcinoma, testicular cancer, and uterine cancer.

### Claim 10 (depends on 8, 9)

The CD16 x Disease Antigen Binding Molecule of any one of claims 8 and 9, wherein said Cancer Antigen is selected from the group consisting of the Cancer Antigens: 19.9, 4.2, A33, ADAM-9, AH6, ALCAM, B1, B7-H3, BAGE, beta-catenin, blood group ALeb/Ley, Burkitt's lymphoma antigen-38.13, C14, CA125, Carboxypeptidase M, CD5, CD19, CD20, CD22, CD23, CD25, CD27, CD28, CD33, CD36, CD40/CD154, CD45, CD56, CD46, CD52, CD56, CD79a/CD79b, CD103, CD123, CD317, CDK4, CEA, CEACAM5/CEACAM6, CO17-1A, CO-43, CO-514, CTA-1, CTLA-4, Cytokeratin 8, D1.1, Di56-22, DR5, E1 series, EGFR, an Ephrin receptor, EphA2, Erb, GAGE, a GD2/GD3/GM2 ganglioside, GICA 19-9, gp100, Gp37, gp75, gpA33, HER2/neu, HMFG, human papillomavirus-E6/human papillomavirus-E7, HMW-MAA, I antigen, IL13Rα2, Integrin β6, JAM-3, KID3, KID31, KS 1/4 pan-carcinoma antigen, L6,L20, LEA, LUCA-2, M1:22:25:8, M18, M39, MAGE, MART, mesothelin, MUC-1, MUM-1, Myl, N-acetylglucosaminyltransferase, neoglycoprotein, NS-10, OFA-1, OFA-2, Oncostatin M, p15, p97, PEM, PEMA, PIPA, PSA, PSMA, prostatic acid phosphate, R24, ROR1, a sphingolipid, SSEA-1, SSEA-3, SSEA-4, sTn, the T cell receptor derived peptide, T5A7, TAG-72, TL5, TNF-receptor, TNF-γ receptor, TRA-1-85, a Transferrin Receptor, 5T4, TSTA, VEGF, a VEGF Receptor, VEP8, VEP9, VIM-D5, and Y hapten, Ley.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The CD16 x Disease Antigen Binding Molecule of any one of claims 1-8, wherein said Disease Antigen is 5T4, B7-H3, CEACAM5/CEACAM6, CD19, CD123, EGRF, EphA2, HER2/neu, IL13Rα2 or VEGF.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7)

The CD16 x Disease Antigen Binding Molecule of any one of claims 1-7, wherein said Disease Antigen is a Pathogen-Associated Antigen.

### Claim 13 (depends on 12)

The CD16 x Disease Antigen Binding Molecule of claim 12, wherein said Pathogen-Associated Antigen is selected from the group consisting of the Pathogen-Associated Antigens: Herpes Simplex Virus infected cell protein (ICP)47, Herpes Simplex Virus gD, Epstein-Barr Virus LMP-1, Epstein-Barr Virus LMP-2A, Epstein-Barr Virus LMP-2B, Human Immunodeficiency Virus gp160, Human Immunodeficiency Virus gp120, Human Immunodeficiency Virus gp41, etc.), Human Papillomavirus E6, Human Papillomavirus E7, human T-cell leukemia virus gp64, human T-cell leukemia virus gp46, and human T-cell leukemia virus gp21.

### Claim 14 (depends on 12, 13)

The CD16 x Disease Antigen Binding Molecule of claim 12 or 13, wherein said Disease Antigen is an HIV env antigen.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The CD16 x Disease Antigen Binding Molecule of any one of claims 1-14, wherein said molecule is:
(A) a diabody, said diabody being a covalently bonded complex that comprises two, or three, four or five polypeptide chains; or
(B) a trivalent binding molecule, said trivalent binding molecule being a covalently bonded complex that comprises three, four or five polypeptide chains, or
(C) a bispecific antibody.

### Claim 16 (depends on 15)

The CD16 x Disease Antigen Binding Molecule of claim 15, wherein said molecule comprises an Fc Region.

### Claim 17 (depends on 16)

The CD16 x Disease Antigen Binding Molecule of claim 16, wherein said Fc Region is of the IgG1, IgG2, IgG3, or IgG4 isotype.

### Claim 18 (depends on 16, 17)

The CD16 x Disease Antigen Binding Molecule of claim 16 or 17, wherein said Fc Region is a variant Fc Region that comprises:
(A) one or more amino acid modifications that reduces the affinity of the variant Fc Region for an FcγR; and/or
(B) one or more amino acid modifications that enhances the serum half-life of the variant Fc Region.

### Claim 19 (depends on 18)

The CD16 x Disease Antigen Binding Molecule of claim 18, wherein:
(A) said modifications that reduces the affinity of the variant Fc Region for an FcγR comprise the substitution of L234A; L235A; or L234A and L235A; and
(B) said modifications that enhances the serum half-life of the variant Fc Region comprise the substitution of M252Y; M252Y and S254T; M252Y and T256E; M252Y, S254T and T256E; or K288D and H435K,
wherein said numbering is that of the EU index as in Kabat.

### Claim 20

A CD16 Binding Molecule, that comprises:
(A) a CDRH1 Domain comprising the amino acid sequence of SEQ ID NO:66;
(B) a CDRH2 Domain comprising the amino acid sequence of SEQ ID NO:67;
(C) a CDRH3 Domain comprising the amino acid sequence of SEQ ID NO:68, or SEQ ID NO:60;
(D) a CDRL1 Domain comprising the amino acid sequence of SEQ ID NO:69 or SEQ ID NO:74;
(E) a CDRL2 Domain comprising the amino acid sequence of SEQ ID NO:70; and
(F) a CDRL3 Domain comprising the amino acid sequence of SEQ ID NO:71, or SEQ ID NO:61.

### Claim 21 (depends on 20)

The CD16 Binding Molecule of claim 20, wherein said molecule comprises:
(A) a VH Domain comprising the amino acid sequence of SEQ ID NO:72, or SEQ ID NO:58;
(B) a VL Domain comprising the amino acid sequence of SEQ ID NO:73, or SEQ ID NO:59;
(C) a VH Domain comprising the amino acid sequence of SEQ ID NO:72 and a VL Domain comprising the amino acid sequence of SEQ ID NO:73;
(D) a VH Domain comprising the amino acid sequence of SEQ ID NO:58 and a VL Domain comprising the amino acid sequence of SEQ ID NO:73;
(E) a VH Domain comprising the amino acid sequence of SEQ ID NO:72 and a VL Domain comprising the amino acid sequence of SEQ ID NO:59; or
(F) a VH Domain comprising the amino acid sequence of SEQ ID NO:58 and a VL Domain comprising the amino acid sequence of SEQ ID NO:59.

### Claim 22

A CD16 Binding Molecule that comprises:
(A) a CDRH1 Domain comprising the amino acid sequence of SEQ ID NO:77;
(B) a CDRH2 Domain comprising the amino acid sequence of SEQ ID NO:78;
(C) a CDRH3 Domain comprising the amino acid sequence of SEQ ID NO:79;
(D) a CDRL1 Domain comprising the amino acid sequence of SEQ ID NO:80;
(E) a CDRL2 Domain comprising the amino acid sequence of SEQ ID NO:81; and
(F) a CDRL3 Domain comprising the amino acid sequence of SEQ ID NO:82.

### Claim 23 (depends on 22)

The CD16 Binding Molecule of claim 22, wherein said molecule comprises:
(A) a VH Domain comprising the amino acid sequence of SEQ ID NO:83 or SEQ ID NO:84;
(B) a VL Domain comprising the amino acid sequence of or SEQ ID NO:85; or
(C) a VH Domain comprising the amino acid sequence of SEQ ID NO:83 or SEQ ID NO:84 and a VL Domain comprising the amino acid sequence of SEQ ID NO:85.

### Claim 24 (depends on 20, 21, 22, 23)

The CD16 Binding Molecule of any one of claims 20-23, wherein said molecule is selected from the group consisting of: an antibody, a multispecific antibody, a Fab′ fragment, a F(ab′)2 fragment, a (Fv) fragment, a single-chain (scFv), a single-chain antibody, a disulfide-linked bispecific Fv (sdFv), a diabody, a trivalent binding molecule, and a CAR-T molecule.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A pharmaceutical composition that comprises the CD16 x Disease Antigen Binding Molecule of any one of claims 1-19 and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 20, 21, 22, 23, 24)

A pharmaceutical composition that comprises the CD16 Binding Molecule, of any one of claims 20-24 and a pharmaceutically acceptable carrier.

### Claim 27 (depends on 25)

Use of the pharmaceutical composition of claim 25 in the treatment of a disease characterized by the expression of said Disease Antigen.

### Claim 28 (depends on 24)

A method for the treatment of a disease characterized by the expression of said Disease Antigen, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 24.

### Claim 29 (depends on 27, 28)

The use of claim 27 or the method of claim 28, wherein said CD16 x Disease Antigen Binding Molecule is capable of binding more than one Disease Antigen and/or more than one epitope of CD16.

### Claim 30 (depends on 27, 28)

The use of claim 27 or the method of claim 28, wherein said CD16 x Disease Antigen Binding Molecule, wherein said Disease Antigen is a Cancer Antigen, and said disease is cancer.

### Claim 31 (depends on 30)

The use or method of claim 30, wherein said cancer is selected from the group consisting of adrenal cancer, bladder cancer, breast cancer, colorectal cancer, gastric cancer, glioblastoma, kidney cancer, non-small-cell lung cancer, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, Burkett's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, non-Hodgkin's lymphoma, small lymphocytic lymphoma, multiple myeloma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, renal cell carcinoma, testicular cancer, and uterine cancer.

### Claim 32 (depends on 30)

The use or method of claim 30, wherein said Cancer Antigen is selected from the group consisting of the Cancer Antigens: 19.9, 4.2, A33, ADAM-9, AH6, ALCAM, B1, B7-H3, BAGE, beta-catenin, blood group ALeb/Ley, Burkitt's lymphoma antigen-38.13, C14, CA125, Carboxypeptidase M, CD5, CD19, CD20, CD22, CD23, CD25, CD27, CD28, CD33, CD36, CD40/CD154, CD45, CD56, CD46, CD52, CD56, CD79a/CD79b, CD103, CD123, CD317, CDK4, CEA, CEACAM5/CEACAM6, CO17-1A, CO-43, CO-514, CTA-1, CTLA-4, Cytokeratin 8, D1.1, Di56-22, DR5, E1 series, EGFR, an Ephrin receptor, EphA2, Erb, GAGE, a GD2/GD3/GM2 ganglioside, GICA 19-9, gp100, Gp37, gp75, gpA33, HER2/neu, HMFG, human papillomavirus-E6/human papillomavirus-E7, HMW-MAA, I antigen, IL13Rα2, Integrin β6, JAM-3, KID3, KID31, KS 1/4 pan-carcinoma antigen, L6,L20, LEA, LUCA-2, M1:22:25:8, M18, M39, MAGE, MART, mesothelin, MUC-1, MUM-1, Myl, N-acetylglucosaminyltransferase, neoglycoprotein, NS-10, OFA-1, OFA-2, Oncostatin M, p15, p97, PEM, PEMA, PIPA, PSA, PSMA, prostatic acid phosphate, R24, ROR1, a sphingolipid, SSEA-1, SSEA-3, SSEA-4, sTn, the T cell receptor derived peptide, T5A7, TAG-72, TL5, TNF-receptor, TNF-γ receptor, TRA-1-85, a Transferrin Receptor, 5T4, TSTA, VEGF, a VEGF Receptor, VEP8, VEP9, VIM-D5, and Y hapten, Ley.

### Claim 33 (depends on 32)

The use or method of claim 32, wherein said Disease Antigen is 5T4, B7-H3, CEACAM5/CEACAM6, CD19, CD123, EGRF, EphA2, HER2/neu, IL13Rα2 or VEGF.

### Claim 34 (depends on 27, 28)

The use of claim 27 or the method of claim 28, wherein said CD16 x Disease Antigen Binding Molecule, wherein said Disease Antigen is a Pathogen-Associated Antigen.

### Claim 36 (depends on 34)

The use or method of claim 34, wherein said Pathogen-Associated Antigen is selected from the group consisting of the Pathogen-Associated Antigens: Herpes Simplex Virus infected cell protein (ICP)47, Herpes Simplex Virus gD, Epstein-Barr Virus LMP-1, Epstein-Barr Virus LMP-2A, Epstein-Barr Virus LMP-2B, Human Immunodeficiency Virus gp160, Human Immunodeficiency Virus gp120, Human Immunodeficiency Virus gp41, etc.), Human Papillomavirus E6, Human Papillomavirus E7, human T-cell leukemia virus gp64, human T-cell leukemia virus gp46, and human T-cell leukemia virus gp21.

### Claim 37 (depends on 35)

The use or method of claim 35, wherein said Disease Antigen is an HIV env antigen.
